**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 73522

**Manuscript Type:** CASE REPORT

**Ultrasound-guided local ethanol injection for fertility-preserving cervical pregnancy accompanied by fetal heartbeat: Two case reports**

Kakinuma T *et al*. Local ethanol injection for cervical pregnancy

Toshiyuki Kakinuma, Kaoru Kakinuma, Yoshio Matsuda, Michitaka Ohwada, Kaoru Yanagida, Hirotsune Kaijima

**Toshiyuki Kakinuma, Kaoru Kakinuma, Yoshio Matsuda, Michitaka Ohwada, Kaoru Yanagida,** Department of Obstetrics and Gynecology, International University of Health and Welfare Hospital, Nasushiobara 329-2763, Japan

**Hirotsune Kaijima,** Minatomirai Yume Clinic, Yokohama 220-0012, Japan

**Author contributions:** Kakinuma T designed the research study and wrote the manuscript; Kakinuma T, Kakinuma K, Ohwada M and Yanagida K performed the research; Matsuda Y and Kaijima H provided help and advice on the study protocol; All authors read and approved the final manuscript.

**Corresponding author: Toshiyuki Kakinuma, MD, PhD, Professor,** Department of Obstetrics and Gynecology, International University of Health and Welfare Hospital, 537-3, Iguchi, Nasushiobara 329-2763, Japan. kakinuma@iuhw.ac.jp

**Received:** December 1, 2021

**Revised:** February 7, 2022

**Accepted: February 27, 2022**

**Published online:**

**Abstract**

BACKGROUND

The incidence of cervical pregnancy is increasing due to the recent widespread application of assisted reproductive technology. Although hysterectomy has been a treatment option, high-sensitivity human chorionic gonadotropin testing and improved accuracy of transvaginal ultrasound imaging have increased possibility of uterine preservation. Dilation and curettage with methotrexate therapy and uterine artery embolization have been reported as treatments with fertility preservation; however, certain disadvantages limit their use.

CASE SUMMARY

In our two reported cases, we avoided massive bleeding and immediately resumed infertility treatment using ultrasound-guided local ethanol injection for cervical pregnancies with fetal heartbeats.

CONCLUSION

This treatment may be a new fertility-preserving option for cervical pregnancy.

**Key Words:** Ultrasonography; Ethanol; Infertility; Fertility preservation; Methotrexate; Case report

Kakinuma T, Kakinuma K, Matsuda Y, Ohwada M, Yanagida K, Kaijima H. Ultrasound-guided local ethanol injection for fertility-preserving cervical pregnancy accompanied by fetal heartbeat: Two case reports. *World J Clin Cases* 2022; In press

**Core Tip:** We describe the use of transvaginal ultrasound-guided local injection of absolute ethanol as a new treatment method for cervical pregnancy that preserves fertility. In both cases, the patients had developed cervical pregnancy through assisted reproductive technology and sought fertility-preserving treatment. A local injection of absolute ethanol allowed resumption of menstruation 2 mo after treatment and early resumption of infertility treatment without any complications. We suggest that local injection of absolute ethanol for cervical pregnancy could be a safe and effective new treatment method.

**INTRODUCTION**

Cervical pregnancies occur in approximately 1 in 9000 pregnancies[1,2]. They are believed to be more common in those with a history of abortion or cesarean delivery, and are more common with assisted reproductive technology than with natural pregnancies[3]. The cervix contains very little smooth muscle, and it is thought that the villi easily infiltrate the muscular layer and form a high degree of placenta accreta. Furthermore, careless intracervical curettage for cervical pregnancy may cause complicated massive bleeding. Therefore, hysterectomy should be considered for treatment.

However, the recent development of high-sensitivity human chorionic gonadotropin (hCG) testing and improved accuracy of transvaginal ultrasound imaging have allowed asymptomatic diagnosis and increased fertility preservation due to early intervention. Dilation and curettage with methotrexate (MTX) therapy[4] and uterine artery embolization (UAE)[5] have been reported as treatments for the preservation of fertility. However, in patients who wish to preserve fertility, MTX therapy poses problems that may include ovarian dysfunction and a delay in resumption of infertility treatment due to the washout period[6]. Furthermore, there are many reported cases of unsuccessful MTX administration in cases accompanied by fetal heartbeat or blood hCG concentration of ≥ 10000 mIU/mL[7]. Moreover, with UAE, the rate of preterm birth in subsequent pregnancies may increase, and placenta accreta may occur[8].

There have been reports on the efficacy and safety of ultrasound-guided local ethanol injection as an alternative to topical MTX therapy in ectopic pregnancy[9,10]. This therapy has the potential to become a treatment option, as it does not require a washout period and has fewer complications than UAE therapy. Nevertheless, reports on this topic are scarce. In this report, we present two cases of cervical pregnancy with fetal heartbeat and elevated blood hCG concentration, in which fertility was preserved using local ethanol therapy.

**CASE PRESENTATION**

***Chief complaints***

**Case 1:** A 39-year-old nulliparous woman achieved pregnancy *via* *in vitro* fertilization-embryo transfer (IVF-ET). Ultrasonographic images at 6 wk 2 d of gestation suggested cervical pregnancy; therefore, she was referred to our hospital for detailed examination and treatment.

**Case 2:** A 33-year-old woman, gravida 2, para 1 had achieved pregnancy *via* IVF-ET. Ultrasound imaging results at 7 wk 6 d of gestation suggested cervical pregnancy; therefore, she was referred to our hospital for further examination and treatment.

***History of present illness***

**Cases 1 and 2:** The patients were asymptomatic aside from the ultrasonographic images suggesting cervical pregnancy.

***History of past illness***

**Cases 1 and 2:** The patients reported no notable past illness.

***Personal and family history***

**Cases 1 and 2:** No notable personal or family medical history.

***Physical examination***

**Case 1:** Findings upon presentation included blood pressure of 128/72 mmHg, pulse rate of 72 beats/min, and body temperature of 36.8 ℃.

**Case 2:** Findings upon presentation included a blood pressure of 104/79 mmHg, pulse rate of 78 beats/min, and body temperature of 36.9 ℃.

***Laboratory examinations***

**Case 1:** Blood testing revealed an elevated hCG concentration of 16346 mIU/mL and no other abnormalities noted.

**Case 2:** Blood testing revealed an elevated hCG concentration of 26930 mIU/mL and no other noteworthy abnormalities.

***Imaging examinations***

**Case 1:** Transvaginal ultrasonography revealed no gestational sac (GS) within the uterine body; however, a 21-mm GS-like mass with a fetal heartbeat was found within the cervix (Figure 1).

**Case 2:** Transvaginal ultrasonography revealed a 30 mm cervical GS with fetal heartbeat, and blood flow was noted around the GS by color Doppler imaging (Figure 2).

**FINAL DIAGNOSIS**

In both cases, based on the findings, cervical pregnancy was diagnosed.

**TREATMENT**

***Case 1***

MTX therapy was offered as a treatment option because of the patient's desire to preserve fertility. The patient declined MTX therapy after learning that side effects may include ovarian dysfunction and that a course of contraception was required during MTX washout. Dilation and curettage with UAE were also presented as options; however, the patient declined these after understanding that UAE may affect subsequent pregnancies. As such, the patient sought other fertility-preserving therapies. Therefore, we offered transvaginal ultrasound-guided local absolute ethanol injection because it allows early resumption of infertility treatment and has little effect on ovarian function and subsequent pregnancy. We also emphasized its efficacy and safety in patients with ectopic pregnancies. We explained that the use of local absolute ethanol injection for cervical pregnancy is an off-label and unestablished treatment at this time. Upon explaining the above, the patient and her family chose this treatment.

The treatment involved local injection of 2.5 mL absolute ethanol around the cervical GS using a 23-gauge percutaneous transhepatic cholangiography (PTC) needle under transvaginal ultrasonic guidance (Hakko Co., Ltd., Nagano, Japan). The blood hCG concentration 2 h after treatment was decreased by 20% from the pretreatment value; therefore, the therapeutic effect was confirmed. However, the blood hCG concentration increased the next day to 18087 mIU/mL; therefore, 2.5 mL absolute ethanol was injected again in the same manner. Thereafter, the blood hCG concentration decreased steadily, and spontaneous passage of the GS was observed 7 d after the second local injection of absolute ethanol. Histopathological examination revealed decidua and chorionic villi.

***Case 2***

The patient and her family sought fertility-preserving treatment. As in Case 1, the patient chose transvaginal ultrasound-guided local absolute ethanol injection among the available fertility-preserving treatments.

Using a 23-gauge PTC needle, 4.0 mL absolute ethanol was locally injected around the cervical GS under transvaginal ultrasonic guidance (Hakko Co., Ltd.). The blood hCG concentration 2 h after treatment was 20% less than the pretreatment value, verifying the therapeutic effect. Thereafter, the blood hCG concentration decreased steadily, and the GS spontaneously passed 6 d after the local injection of absolute ethanol. Histopathological examination revealed decidua and chorionic villi.

**OUTCOME AND FOLLOW-UP**

***Case 1***

On day 17, the blood hCG concentration had decreased to 198 mIU/mL, and no complications due to local ethanol injection were observed during follow-up. Two months after local ethanol therapy, menstruation had resumed, and infertility treatment was re-initiated.

***Case 2***

On day 10, the blood hCG concentration had decreased to 116 mIU/mL, and only a small amount of vaginal bleeding was noted during follow-up. In addition, no complications due to local ethanol injection were noted. Two months after local ethanol therapy, menstruation had resumed, and infertility treatment was re-initiated.

**DISCUSSION**

The patients in this report developed cervical pregnancy through assisted reproductive technology. Under these circumstances, many patients wish to preserve their fertility. Such patients often choose MTX therapy or UAE, both of which have high rates of treatment success[4,5] and postoperative pregnancy[11]. However, MTX therapy and UAE also have disadvantages for patients who desire fertility preservation. In a study of 35 patients with a history of MTX treatment for cervical pregnancy, oocyte yields during *in vitro* fertilization were 10.1 ± 3.9 before treatment and 7.8 ± 3.6 after treatment, suggesting that MTX therapy caused a decrease in the number of oocytes. It has been reported that a decrease in oocyte count leads to a decrease in the number of collected eggs[6], and because MTX therapy affects the ovaries, it may also affect fertility preservation. Furthermore, when MTX is used, a 4–6-mo contraception period is required after surgery for washout[12,13], which delays the resumption of fertility treatment. Because patients under infertility treatment are becoming older, the best treatment method should allow early resumption of infertility treatment.

In UAE, postoperative fever is the most common complication, and pain, endometritis, intrauterine adhesions, uterine necrosis, and ovarian dysfunction may also occur[14-16]. According to Hardeman *et al*, 14 of 53 patients who underwent UAE for obstetrical bleeding desired subsequent pregnancy (all gelatin embolization cases), and 12 of these patients conceived and had successful delivery[17]. These results indicate relatively high rates of postoperative fertility. However, in post-UAE pregnancies, there have been reports of significant increases in miscarriage rate, postpartum bleeding, preterm birth rate, and fetal position abnormalities, and there have been case reports of intrauterine growth restriction[8]. This emphasizes the need for strict perinatal management in post-UAE pregnancies.

In this report, transvaginal ultrasound-guided local injection of absolute ethanol was performed as a new treatment method replacing MTX therapy and UAE. Previously, we reported the efficacy and safety of transvaginal ultrasound-guided local absolute ethanol injection in ectopic pregnancies[9,10]. This treatment method involves the local injection of absolute ethanol around the implantation site under ultrasonic guidance. Its therapeutic effect can be determined earlier than in MTX therapy since a 10%-30% decrease in blood hCG concentration can be confirmed within 2 h of injection. We believe that absolute ethanol dehydrates and denatures the villous tissue, and that acute tissue changes reduce the blood hCG concentration within a short period of time. Therefore, we believe that these mechanisms are effective in patients such as ours, who had high blood hCG concentrations and fetal heartbeats—factors associated with unsuccessful MTX therapy. Furthermore, because no massive bleeding was observed after local injection of absolute ethanol, we believe that these mechanisms are hemostatic and may also be an effective treatment for cervical pregnancy accompanied by genital bleeding in patients who desire fertility preservation.

Absolute ethanol administration may also be effective in other transvaginal procedures, as there is a low possibility of iatrogenic infection. The therapy requires no anesthesia because the small needles cause less bleeding and pain, and the procedure is also more affordable than MTX therapy. This mitigates the physical and financial burdens of patients. In addition, when repeated administration is required for persistent ectopic pregnancy, side effects of anticancer drugs, such as MTX, also become a problem. However, injection of absolute ethanol causes only a local effect, which means that it can be repeated for persistent ectopic pregnancies. In Case 1, two local injections of absolute ethanol were administered for persistent ectopic pregnancy; however, no side effects were observed with this treatment.

In our two reported cases, blood hCG concentration was high and fetal heartbeat was present, which are risk factors for unsuccessful MTX therapy. However, the local injection of absolute ethanol was still able to preserve fertility. In both cases, local injection of absolute ethanol allowed resumption of menstruation 2 mo after treatment and early resumption of infertility treatment without any complications. Based on these results, we suggest that local injection of absolute ethanol for cervical pregnancy could be a safe and effective new treatment method.

**CONCLUSION**

In this report, we presented two cases of cervical pregnancy with elevated blood hCG concentrations and fetal heartbeats. Each underwent fertility-preserving treatment with local ethanol injection. The outcomes suggested that this treatment method may avoid the complications of MTX therapy and UAE and may be an option for patients who desire fertility preservation.

**REFERENCES**

1 **Ushakov FB**, Elchalal U, Aceman PJ, Schenker JG. Cervical pregnancy: past and future. *Obstet Gynecol Surv* 1997; **52**: 45-59 [PMID: 8994238 DOI: 10.1097/00006254-199701000-00023]

2 **Vela G**, Tulandi T. Cervical pregnancy: the importance of early diagnosis and treatment. *J Minim Invasive Gynecol* 2007; **14**: 481-484 [PMID: 17630167 DOI: 10.1016/j.jmig.2006.11.012]

3 **American College of Obstetricians and Gynecologists**. ACOG Practice Bulletin No.94: Medical management of ectopic pregnancy. *Obstet Gynecol* 2008; **111**: 1479-1485 [PMID: 18515537 DOI: 10.1097/AOG.0b013e31817d201e]

4 **Adabi K**, Nekuie S, Rezaeei Z, Rahimi-Sharbaf F, Banifatemi S, Salimi S. Conservative management of cervical ectopic pregnancy: systemic methotrexate followed by curettage. *Arch Gynecol Obstet* 2013; **288**: 687-689 [PMID: 23525594 DOI: 10.1007/s00404-013-2807-y]

5 **Martinelli P**, Maruotti GM, Oppedisano R, Agangi A, Mazzarelli LL, Votino C, Quarantelli M, Iaccarino V. Is uterine artery embolization for cervical ectopic pregnancy always safe? *J Minim Invasive Gynecol* 2007; **14**: 758-763 [PMID: 17980340 DOI: 10.1016/j.jmig.2007.05.017]

6 **McLaren JF**, Burney RO, Milki AA, Westphal LM, Dahan MH, Lathi RB. Effect of methotrexate exposure on subsequent fertility in women undergoing controlled ovarian stimulation. *Fertil Steril* 2009; **92**: 515-519 [PMID: 18829004 DOI: 10.1016/j.fertnstert.2008.07.009]

7 **Kirk E**, Condous G, Haider Z, Syed A, Ojha K, Bourne T. The conservative management of cervical ectopic pregnancies. *Ultrasound Obstet Gynecol* 2006; **27**: 430-437 [PMID: 16514619 DOI: 10.1002/uog.2693]

8 **Goldberg J**, Pereira L, Berghella V. Pregnancy after uterine artery embolization. *Obstet Gynecol* 2002; **100**: 869-872 [PMID: 12423843 DOI: 10.1016/s0029-7844(02)02347-5]

9 **Kaijima H**, Osada H, Kato K, Segawa T, Takehara Y, Teramoto S, Kato O. The efficacy and safety of managing ectopic pregnancies with transvaginal ultrasound-guided local injections of absolute ethanol. *J Assist Reprod Genet* 2006; **23**: 293-298 [PMID: 16832599 DOI: 10.1007/s10815-006-9037-1]

10 **Kakinumaa T,** Kakinumaa K, Kaijima H. The Efficacy and Safety of Managing Interstitial Pregnancies with Transvaginal Ultrasound-Guided Local Injections of Absolute Ethanol. *Annal Cas Rep Rev* 2020;ACRR-152[DOI: 10.39127/2574-5747/ACRR:1000152]

11 **Ornan D**, White R, Pollak J, Tal M. Pelvic embolization for intractable postpartum hemorrhage: long-term follow-up and implications for fertility. *Obstet Gynecol* 2003; **102**: 904-910 [PMID: 14672461 DOI: 10.1016/s0029-7844(03)00769-5]

12 **Gougeon A**. Dynamics of follicular growth in the human: a model from preliminary results. *Hum Reprod* 1986; **1**: 81-87 [PMID: 3558758 DOI: 10.1093/oxfordjournals.humrep.a136365]

13 **Strauss J**, Barbieri R, Gargiulo A. The ovarian life cycle. In: Strauss JF, Barbieri RL, editors. Yen and Jaffeʼs reproductive endocrinology: physiology, pathophysiology, and clinical management. 5th ed. Philadelphia: Elsevier Saunders, 2004: 213 [DOI: 10.1016/j.fertnstert.2004.09.010]

14 **Badawy SZ**, Etman A, Singh M, Murphy K, Mayelli T, Philadelphia M. Uterine artery embolization: the role in obstetrics and gynecology. *Clin Imaging* 2001; **25**: 288-295 [PMID: 11566093 DOI: 10.1016/s0899-7071(01)00307-2]

15 **Vegas G**, Illescas T, Muñoz M, Pérez-Piñar A. Selective pelvic arterial embolization in the management of obstetric hemorrhage. *Eur J Obstet Gynecol Reprod Biol* 2006; **127**: 68-72 [PMID: 16229935 DOI: 10.1016/j.ejogrb.2005.09.008]

16 **Hong TM**, Tseng HS, Lee RC, Wang JH, Chang CY. Uterine artery embolization: an effective treatment for intractable obstetric haemorrhage. *Clin Radiol* 2004; **59**: 96-101 [PMID: 14697382 DOI: 10.1016/j.crad.2003.08.007]

17 **Hardeman S**, Decroisette E, Marin B, Vincelot A, Aubard Y, Pouquet M, Maubon A. Fertility after embolization of the uterine arteries to treat obstetrical hemorrhage: a review of 53 cases. *Fertil Steril* 2010; **94**: 2574-2579 [PMID: 20381035 DOI: 10.1016/j.fertnstert.2010.02.052]

**Footnotes**

**Informed consent statement:** The study was approved by the Ethics Committee of the International University of Health and Welfare Hospital (Approval date: July 21, 2021; Approval number 21-B-8). The patients provided consent after receiving written and verbal explanation of the study protocol.

**Conflict-of-interest statement:** The authors declare no competing interests.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 1, 2021

**First decision:** January 22, 2022

**Article in press:**

**Specialty type:** Obstetrics and gynecology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Feng J, China; Zhao Q, China **S-Editor:** Gong ZM **L-Editor:** A **P-Editor:** Gong ZM

**Figure Legends**



**Figure 1** **Transvaginal ultrasound findings in Case 1.** A gestational sac with fetal heartbeat was found in the cervix.



**Figure 2** **Transvaginal ultrasound findings in Case 2.** A 30 mm gestational sac with fetal heartbeat was found in the cervix, and blood flow was noted around the sac by color Doppler imaging.